Skip to content

Insider · CIK 0002076371

Michael Andrew Holloway

director

Files at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.). First filing -, latest -.

In brief

Michael Andrew Holloway files SEC Form 4 as director at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.

A track record needs three past buys with six months of prices behind them; Michael Andrew Holloway has 0, so none is measured yet.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, 4 in all, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Jul 1, 2026NMAD
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
AGrant or award
Common Stock
+15,000$0.00$040,000Jul 2, 2026
Apr 15, 2026NMAD
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
AGrant or award
Common Stock
+25,000--25,000Apr 17, 2026
Apr 15, 2026NMAD
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
DDisposition to issuer
Options to Purchase Common Stockderivative
-25,000--0Apr 17, 2026
Aug 15, 2025NMAD
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
AGrant or award
Options to Purchase Common Stockderivative
+25,000$0.00$025,000Aug 18, 2025

Questions about Michael Andrew Holloway

Answered from the filings on this page, as of the latest one.

Is Michael Andrew Holloway buying or selling?

Michael Andrew Holloway has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.

How did Michael Andrew Holloway's past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael Andrew Holloway has 0.

Where does Michael Andrew Holloway file Form 4?

Michael Andrew Holloway has filed Form 4 at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Michael Andrew Holloway: insider trades and track record | InsiderTell